James D. Neaton
Affiliations: | University of Minnesota, Twin Cities, Minneapolis, MN |
Area:
Public Health, Biostatistics BiologyGoogle:
"James Neaton"Cross-listing: PHTree
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Cunningham JW, Ferreira JP, Deng H, et al. (2020) Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF. Jacc. Heart Failure |
| Ghazi L, Baker JV, Sharma S, et al. (2019) Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial. American Journal of Hypertension |
| Kotalik A, Eaton A, Lian Q, et al. (2019) A win ratio approach to the re-analysis of Multiple Risk Factor Intervention Trial. Clinical Trials (London, England). 1740774519868233 |
| Castillo-Mancilla JR, Phillips AN, Neaton JD, et al. (2019) Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study. Journal of the International Aids Society. 22: e25297 |
| Sharma S, Schlusser KE, de la Torre P, et al. (2019) The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection. Aids (London, England). 33: 1335-1344 |
| Lodi S, Phillips A, Lundgren J, et al. (2019) Effect estimates in randomized trials and observational studies: comparing apples with apples. American Journal of Epidemiology |
| Greenberg B, Neaton JD, Anker SD, et al. (2019) Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. Jama Cardiology |
| Boatman JA, Baker JV, Emery S, et al. (2019) Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression among Participants Initiating Antiretroviral Treatment with CD4+ Counts > 500 cells/mm3: Findings from the Strategic Timing of AntiRetroviral Treatment (START) Trial. Journal of Acquired Immune Deficiency Syndromes (1999) |
| Ghazi L, Baker JV, Sharma S, et al. (2019) Abstract P172: Association of Interleukin 6 With Hypertension in HIV Positive Participants in the Strategic Timing of Antiretroviral Treatment (START) Trial Circulation. 139 |
| Blumberg E, Gary C, Young JH, et al. (2019) 2670. Clostridioides difficile Infection (CDI) in Solid-Organ (SOT) and Hematopoietic Stem Cell Transplant (HCT) Recipients: A Prospective Multinational Study Open Forum Infectious Diseases. 6: S936-S936 |